Supplementary Table 2 from Cemiplimab in Locally Advanced or Metastatic Secondary Angiosarcomas (CEMangio): A Phase II Clinical Trial and Biomarker Analyses
Stefan G. van Ravensteijn(Radboud University Nijmegen), Ingrid M.E. Desar(Radboud University Nijmegen), Uta Flucke(Princess Máxima Center), Tessa J.J. de Bitter(Radboud University Nijmegen), Mark A.J. Gorris(Salk Institute for Biological Studies), Yvonne M.H. Versleijen‐Jonkers(Radboud University Nijmegen), Jacco J. de Haan(University Medical Center Groningen), Suzanne E. J. Kaal(Radboud University Nijmegen), Melissa H.S. Hillebrandt-Roeffen(Radboud University Nijmegen), Hans Gelderblom(Leiden University Medical Center), Carla M.L. van Herpen(Radboud University Nijmegen), Annemarie Boleij(Radboud University Nijmegen), Minke Smits(Radboud University Nijmegen), Frank M. Speetjens(Leiden University Medical Center), Maikel J.L. Nederkoorn(Radboud University Nijmegen), Han J. Bonenkamp(Radboud University Nijmegen), Thomas H. A. Ederveen(Radboud University Nijmegen), Alem Gusinac(Radboud University Nijmegen), Kalijn F. Bol(Radboud University Nijmegen)
Cited by 0
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k